Journal profile · Oncology
Oncology
ISSN 0030-2414 · eISSN 1423-0232 · S. Karger AG · SWITZERLAND · Bimonthly · Founded 1967
Oncology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.82; hybrid open access; median 90 days to acceptance (100 articles, last 24 months); community-reported acceptance: fairly easy; 113 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Oncology is published by S. Karger AG and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Treatment and Pharmacology, Hepatocellular Carcinoma Treatment and Prognosis and Colorectal Cancer Treatments and Studies, together about 20.2% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Your Source for Important Clinical and Translational Laboratory Studies from Around the World This journal works to accelerate the translation of experimental results into the clinic and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically relevant knowledge of cancer and improve the outcome of prevention, diagnosis, and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted), and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a section which focuses on rapid peer review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of ensuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editor-in-chief Maurie MarkmanPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Treatment and PharmacologyMedicine6.9%
- Hepatocellular Carcinoma Treatment and PrognosisMedicine6.8%
- Colorectal Cancer Treatments and StudiesMedicine6.6%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance6.5%
- Human auditory perception and evaluationEngineering6%
- Gastric Cancer Management and OutcomesMedicine5.6%
- Lung Cancer Treatments and MutationsMedicine5.2%
- Lung Cancer Research StudiesMedicine4.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.82LetPub ·
- Impact factor (publisher)
- 1.9Publisher website ·
- CiteScore 2026-06
- 3.5LetPub ·
- CiteScore (publisher)
- 3.5Publisher website ·
- SJR 2026-06
- 0.6LetPub ·
- SNIP 2026-06
- 0.59LetPub ·
- h-index
- 92LetPub ·
- h-index
- 125OpenAlex ·
- i10-index
- 3,399OpenAlex ·
- 2-year mean citedness
- 1.8OpenAlex ·
- Self-citation rate
- 5.3%LetPub ·
- Share of gold OA articles
- 13.37%LetPub ·
Volume
- Articles per year
- 105LetPub ·
Articles by year OpenAlex count · 6,618 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 43 | 21 | 4 |
| 2025 | 113 | 28 | 131 |
| 2024 | 128 | 52 | 375 |
| 2023 | 150 | 51 | 789 |
| 2022 | 97 | 34 | 566 |
| 2021 | 108 | 24 | 1,322 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
90 daysMedian, submission to acceptance · P25–P75 69 days – 139 days
- Acceptance to online
- median 20 days (100 articles)
- Submission to online
- median 117 days
- Sample
- 100 articles with submission and acceptance dates (244 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Acceptance rate (publisher)
- 29.2%Publisher website ·
- Submission to first decision
- 28 daysPublisher website ·
- Submission to final decision
- 42 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websitePeer review
- Peer review
Rapid peer review and publication of short reports of phase 1 and phase 2 clinical cancer trials, regardless of trial conclusions regarding efficacy or toxicity. Model summary
A unique feature of the journal is a section which focuses on rapid peer review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of ensuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- S. Karger AG
- Country or region
- SWITZERLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1967
- ISSN
- 0030-2414
- Electronic ISSN
- 1423-0232
- Latest issue on the website
- Volume 104, Issue 8 (August 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Oncology
What CAS zone is Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Oncology is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Oncology?
The latest impact factor listed by LetPub is 1.82; CiteScore 3.5, h-index 125.
How long does peer review take at Oncology?
Based on the dates recorded on 100 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 90 days (interquartile range 69–139 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”; the journal's website gives an acceptance rate of 29.2%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Oncology?
According to LetPub and DOAJ records, Oncology is indexed in SCIE and Scopus.
Is Oncology open access, and what is the APC?
Oncology is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .